In which patients will you consider a shorter course of adjuvant Herceptin?

Topics: Breast Cancer • Medical Oncology

The PERSEPHONE trial to be presented at ASCO suggests 6 months of Herceptin is non-inferior to 12 months in early Her2 postive disease.

Answer from: Medical Oncologist at Academic Institution

At this point, I would not treat any patients with short term trastuzumab. The Short-Her study had very wide confidence intervals for non-inferiority, and there was a numerically superior 2.2% improvement in DFS in the long (standard) trastuzumab arm. Additionally, in the patients with the wors...

Comments

Medical Oncologist at University of Pittsburgh School of Medicine
I am going to add that the PERSEPHONE trial of ove...

Answer from: Medical Oncologist at Academic Institution

I agree with @Adam Brufsky. Notably, the FinHer adjuvant chemo+/- trastuzumab study evaluated the impact of chemotherapy with or without only 9 weeks of trastuzumab and demonstrated hazard ratios similar to those reported in other studies. However, one year of trastuzumab has remained the standard f...

Related Questions